Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

DiNardo

Showing results (1031-1040 of 1,482) with videos related to

Pageof 149
Sort By:
Blood Cells, Molecules & Diseases|April 3, 2019
SMIM1 intron 2 gene variations leading to variability in Vel antigen expression among Brazilian blood donorsMarcia Regina Dezan, Abel Costa-Neto, Carolina Nunes Gomes, et al.
Leukemia & Lymphoma|April 20, 2022
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemiaNicholas J Short, Gautam Borthakur, Naveen Pemmaraju, et al.
Blood Advances|March 8, 2023
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensityAlexandre Bazinet, Tapan Kadia, Nicholas J Short, et al.
Leukemia|June 18, 2020
Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortalityGhayas C Issa, Hagop M Kantarjian, Lianchun Xiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2024
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AMLNicholas J Short, Naval Daver, Courtney D Dinardo, et al.
Frontiers in Immunology|October 16, 2023
Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of conceptMuhammad Aminu, Naval Daver, Myrna C B Godoy, et al.
American Journal of Hematology|September 4, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variantsAlex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.
Blood Advances|August 16, 2022
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndromeCourtney D DiNardo, Sangeetha Venugopal, Curtis Lachowiez, et al.
Blood|July 7, 2022
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNHartmut Döhner, Andrew H Wei, Frederick R Appelbaum, et al.
Cancer|April 13, 2018
Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000Hagop M Kantarjian, Courtney D DiNardo, Graciela M Nogueras-Gonzalez, et al.
Pageof 149

Showing results (1031-1040 of 1,482) with videos related to

Sort By:
Pageof 149
Blood Cells, Molecules & Diseases|April 3, 2019
SMIM1 intron 2 gene variations leading to variability in Vel antigen expression among Brazilian blood donorsMarcia Regina Dezan, Abel Costa-Neto, Carolina Nunes Gomes, et al.
Leukemia & Lymphoma|April 20, 2022
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemiaNicholas J Short, Gautam Borthakur, Naveen Pemmaraju, et al.
Blood Advances|March 8, 2023
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensityAlexandre Bazinet, Tapan Kadia, Nicholas J Short, et al.
Leukemia|June 18, 2020
Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortalityGhayas C Issa, Hagop M Kantarjian, Lianchun Xiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2024
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AMLNicholas J Short, Naval Daver, Courtney D Dinardo, et al.
Frontiers in Immunology|October 16, 2023
Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of conceptMuhammad Aminu, Naval Daver, Myrna C B Godoy, et al.
American Journal of Hematology|September 4, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variantsAlex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.
Blood Advances|August 16, 2022
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndromeCourtney D DiNardo, Sangeetha Venugopal, Curtis Lachowiez, et al.
Blood|July 7, 2022
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNHartmut Döhner, Andrew H Wei, Frederick R Appelbaum, et al.
Cancer|April 13, 2018
Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000Hagop M Kantarjian, Courtney D DiNardo, Graciela M Nogueras-Gonzalez, et al.
Pageof 149